OncoLize presents its breakthrough results in pre-clinical pancreatic tumor treatment

OncoLize presents its breakthrough results in pre-clinical pancreatic tumor treatment

Leiden, 5th September 2024


OncoLize presents its breakthrough results in pre-clinical pancreatic tumor treatment at upcoming events:

  • 24-26th September 2024 - RESI Conference - Boston, USA
  • 28-29th October 2024 - PODD Conference - Boston, USA
  • 4-6 November 2024 - Bio-Europe - Stockholm, Sweden


Drug delivery start-up OncoLize from the Netherlands recently achieved a remarkable 100% survival rate of mice through stopping tumor growth in rapidly growing pancreatic tumors. This was done in collaboration with Leiden University Medical Center, by directly injecting its lead product ChemGemTMinto these tumors using a Patient Derived Xenograft (PDX)-mouse model.


Further studies involving ChemGemTMinjections into highly aggressive and drug-resistant KPC3-PDAC xenograft tumors also exhibited a significant decrease in tumor growth rate and with significant prolonged survival.

Moreover, no detrimental effects on animal weight, blood parameters, or organs were observed, while biomarkers for tumor proliferation were reduced in the ChemGemTMtreatment.

In clear contrast, systemic treatment with an equivalent dose of the standard-of-care Gemcitabine or sham injections in tumors did not not slow down tumor growth or show any significant improvement on survival rates.


ChemGemâ„¢ is an injectable drug depot that slowly releases Gemcitabine at high concentrations directly inside pancreatic tumors. The ChemoGellâ„¢ platform for localized and slow release has also been demonstrated in vivo with other well-known oncology drugs in a Lung-cancer model.


The next steps for OncoLize involve expediting the development of ChemGemTMby conducting non-clinical safety and toxicity assessments, scaling up CMC production, and compiling the necessary documentation for Clinical Trial Application in preparation for First-in-Human clinical trials.